Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2010.

Cash, cash equivalents, and short-term investments at September 30, 2010 were $303.3 million as compared to $396.2 million at December 31, 2009.

Revenue for the third quarter of 2010 increased to $37.9 million as compared to $10.2 million in the third quarter of 2009.  The increase in revenue year over year is largely the result of the amortization of the $125 million milestone payment received from AstraZeneca in September 2009 under the partnership agreement for NKTR-118.  

Total operating costs and expenses in the third quarter of 2010 were $44.2 million compared to $39.1 million in the third quarter 2009. The increase in total operating costs and expenses was primarily due to an increase in research and development expenses.

Research and development expenses were $27.7 million and increased by 20% in the third quarter of 2010 as compared to $23.0 million for the same quarter in 2009.  General and administrative expense increased slightly to $10.2 million in the third quarter 2010 from $9.9 million in the third quarter of 2009.

“Nektar’s continued productivity in research and development has resulted in a deep pipeline of programs that range from those in preclinical research to those preparing for Phase 3,” said Howard W. Robin, President and Chief Executive Officer of Nektar.  “With our Phase 2 data this year from our exciting oncology candidate, NKTR-102, and the preclinical data from our new opioid candidate, NKTR-181, we continue to demonstrate the value of Nektar’s proprietary polymer conjugate technology.”

Net loss for the third quarter ended September 30, 2010 decreased to $8.7 million or $0.09 per share
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... 19, 2014  For Cloud Pharmaceuticals, Inc., a ... development, partnering is an integral part of its ... new drugs and identify early stage, preclinical, IND, ... their development. The company also partners with funds ... business model, Cloud Pharmaceuticals will be participating in ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Calif., Jan. 27, 2011 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... release unaudited financial results for the quarter ended December ... 2011.  Keith Katkin, President and Chief Executive Officer, Randall ... and Christine Ocampo, Vice President, Finance, will host an ...
... SAN DIEGO, Jan. 27, 2011 Profil™ Institute for ... early phase clinical trials for diabetes and obesity, announced ... speaker at the Ramanbhai Foundation 5th International Symposium and ... The Ramanbhai Foundation,s International Symposium will be ...
Cached Medicine Technology:Profil Institute's CEO Presenting on Early Phase Clinical Research in India 2Profil Institute's CEO Presenting on Early Phase Clinical Research in India 3
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 The ... help businesses and manufacturers perform tests on items ranging ... an increasingly regulated society, pressure on operators to ensure ... than ever. A greater number of government safety regulations ... manufacturers' goods prior to sale. Although revenue briefly dipped ...
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... Discount-Dress.com, a company that ... announced its decision to implement a new shopping cart ... ladies across the world. Furthermore, the company has unveiled ... , The new items come in fashionable designs; ... up to 56 percent off. "We are happy to ...
(Date:9/21/2014)... Rio, Colorado (PRWEB) September 21, 2014 ... Colorado, ten teams of disabled and able-bodied athletes rafted ... and completed a ropes course in pursuit of outdoor ... from national non-profit World T.E.A.M. Sports, disabilities proved ... athletes who successfully completed the three stage event. , ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... smoke. According to a recent study researchers find smoking during ... having a baby with a cleft lip. ,The study, ... their babies were about six months old. Researchers asked about ... many cigarettes she smoked and whether she was exposed to ...
... of osteoarthritis the major cause of disability in ... a few weeks // say researchers according to ... in Europe and the United States recommend the ... to relieve osteoarthritis pain. ,Researchers explain many ...
... could be the first step in the path for a ... first time they have found a successful way to deliver ... mouse. ,Gene therapy for muscular dystrophy has been ... the whole body has been a major obstacle for scientists. ...
... drug for the treatment of alcohol dependence. But one of ... which can reduce medication compliance and can be absorbed // ... injection of naltrexone and the benefit of its use for ... they were randomly assigned to get an injection of naltrexone ...
... clinical trial of people infected with both HIV and hepatitis ... their study, patients who are treated with a newer combination ... of HCV than those who receive standard therapy. ,The ... estimated 1 million Americans infected with HIV also have HCV, ...
... low-fat salad dressing anymore. New research shows fats actually ... ,Researchers studied men and women between ages 19 ... with salad dressing that contained zero, six or 28 ... 11 hours following each meal. ,Results showed that ...
Cached Medicine News:
... LH Ovulation Predicting Test is a qualitative ... Hormone (hLH) in human urine to predict ... by the elevation of human luteinizing hormone ... period starts, hLH has a brief, significant ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Shandon Varistain 24-4 ... stainer designed to offer simplicity ... cytology staining applications. It is ... load and continuous throughput. ...
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: